As of November 10, 2026, Savara Inc is a publicly traded company (Nasdaq: SVRA). The largest holder reporting an active stake on Schedule 13D is Growth Equity Opportunities 17, LLC, at 12%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Venrock Healthcare Capital Partners III, L.P. (9.9%), Dapice Joshua J. (6.9%), Deerfield Mgmt, L.P. (6.74%) (Schedule 13D/A, November 14, 2025).
Is this your company?
About to sign with, pay or invest in Savara Inc? See the free Snapshot first.
Free to see. No signup.
Is Savara Inc a real, registered company?
- Savara Inc. files with the SEC under CIK 1160308 (its SEC filings).
- Its shares are listed under the ticker SVRA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Austin, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Savara Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Robert Lutz, Chief Financial and Operating Officer (Form 8-K filed 2026-06-08). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names TCG Crossover GP I, LLC (filed 2026-02-17).
Who are Savara Inc's owners and officers?
Savara Inc: incorporated in Delaware; business address in Austin, Texas; industry Pharmaceutical Preparations (Form D, 2026-06-08).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-02-17 | Tcg Crossover Gp I, LLC | 6.1% |
| Schedule 13G/A, 2026-02-17 | Venrock Healthcare Capital Partners Iii, L.P. | 9.9% |
| Schedule 13G/A, 2026-02-13 | Nantahala Capital Management, LLC | 3.61% |
| Schedule 13G/A, 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 4.1% |
| Schedule 13G/A, 2026-02-05 | Dapice Joshua J. | 6.9% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.4% |
| Schedule 13G/A, 2025-11-14 | Vestal Point Capital, LP | 2.3% |
| Schedule 13G, 2025-11-14 | Nantahala Capital Management, LLC | 5.08% |
| Schedule 13D/A, 2025-11-14 | Growth Equity Opportunities 17, LLC | 12% |
| Schedule 13G/A, 2025-11-14 | Venrock Healthcare Capital Partners Iii, L.P. | 7.3% |
| Schedule 13G, 2025-11-05 | Deerfield Mgmt, L.P. | 6.74% |
| Schedule 13G/A, 2025-10-17 | Blackrock, Inc. | 4.8% |
Questions about who owns Savara Inc
Who owns Savara Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Savara Inc: Growth Equity Opportunities 17, LLC (12%, Schedule 13D/A, filed 2025-11-14), Venrock Healthcare Capital Partners Iii, L.P. (9.9%, Schedule 13G/A, filed 2026-02-17), Dapice Joshua J. (6.9%, Schedule 13G/A, filed 2026-02-05), Deerfield Mgmt, L.P. (6.74%, Schedule 13G, filed 2025-11-05) and Tcg Crossover Gp I, LLC (6.1%, Schedule 13G/A, filed 2026-02-17); 1 more is listed above.
Who are the largest shareholders of Savara Inc?
By the share each holder's latest filing reports, the largest holders of Savara Inc on this page are Growth Equity Opportunities 17, LLC (12%), Venrock Healthcare Capital Partners Iii, L.P. (9.9%) and Dapice Joshua J. (6.9%).
When did Growth Equity Opportunities 17, LLC buy into Savara Inc?
The filings give report dates, not purchase dates. The earliest filing from Growth Equity Opportunities 17, LLC on this page is the Schedule 13D/A, filed 2025-11-14, reporting 12%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Savara Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Savara Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Savara Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-08 | Robert Lutz | Chief Financial and Operating Officer | appointed | 2026-07-15 |
Which insiders own Savara Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 2,533,642 shares (1.1% of shares outstanding) (Form 4, 2025-12-19).
- , the chief executive and a director: 1,188,050 shares (0.54% of shares outstanding) (Form 4, 2025-12-16).
- , the chief financial officer: 536,032 shares (0.24% of shares outstanding) (Form 4, 2026-06-22).
- , the chief legal officer: 519,232 shares (0.24% of shares outstanding) (Form 4, 2025-12-16).
- , the chief business officer: 371,712 shares (0.17% of shares outstanding) (Form 4, 2025-12-16).
Shares outstanding: 220,623,511 as of 2026-11-09, from the company's latest SEC cover page.
How much has Savara Inc raised?
No fundraising or offering filing from Savara Inc is on file with us.
Keep reading
More on Savara Inc and the records around it.
Savara Inc elsewhere on the record
- Leadership changes Jun 2026
- 5%+ stake filings Feb 2026
Companies that share a holder
- TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Entrada Therapeutics, Inc. (Aug 2026), Vistagen Therapeutics, Inc. (Aug 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/savara